Drug:
Reaction: DISEASE PROGRESSION
20250101 - 20251231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 25115984 |
CN |
78 | 1 |
Disease progression, |
||||
GLOFITAMAB, |
||||
| 102 | 25116007 |
PK |
41 | 2 |
Disease progression, |
||||
BEVACIZUMAB, |
||||
| 103 | 25116281 |
IN |
13 | 2 |
Renal impairment, Disease progression, Drug ineffective for unapproved indication, |
||||
FUROSEMIDE, FUROSEMIDE, ENALAPRIL, SPIRONOLACTONE, DIGOXIN, PENICILLIN G, METOLAZONE, FUROSEMIDE, |
||||
| 104 | 25116353 |
US |
66 | 1 |
Squamous cell carcinoma of skin, Paradoxical drug reaction, Disease progression, Metastases to lung, Drug ineffective, |
||||
CAPECITABINE, CAPECITABINE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, PREDNISONE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 105 | 25116540 |
IN |
1 | |
Disease progression, |
||||
| 106 | 25116864 |
FI |
90 | 1 |
Death, Disease progression, |
||||
AVELUMAB, |
||||
| 107 | 25117214 |
HR |
66 | 2 |
Disease progression, Metastases to lymph nodes, Metastases to bladder, Metastases to uterus, |
||||
DABRAFENIB, TRAMETINIB, |
||||
| 108 | 25117332 |
CN |
66 | 1 |
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 109 | 25117441 |
CN |
59 | 1 |
Disease progression, Drug ineffective, Off label use, |
||||
TRASTUZUMAB, TRASTUZUMAB, CAPECITABINE, CAPECITABINE, OXALIPLATIN, OXALIPLATIN, PACLITAXEL, PACLITAXEL, NIVOLUMAB, NIVOLUMAB, |
||||
| 110 | 25117541 |
US |
44 | 1 |
Disease progression, Drug ineffective, |
||||
CARBOPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, PREDNISONE, TESTOSTERONE, TESTOSTERONE,, CABAZITAXEL, SIPULEUCEL-T, ABIRATERONE ACETATE, ABIRATERONE, ATEZOLIZUMAB, CABOZANTINIB, PEMBROLIZUMAB, DAROLUTAMIDE, APALUTAMIDE, |
||||
| 111 | 25117587 |
IR |
17 | 2 |
Respiratory failure, Disease progression, Leukopenia, Dyspnoea, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 112 | 25117589 |
HR |
50 | 1 |
Stomatitis, Anaemia, Haematochezia, Hypertension, Disease progression, Metastases to central nervous system, |
||||
PAZOPANIB, PAZOPANIB HYDROCHLORIDE, PAZOPANIB, PAZOPANIB HYDROCHLORIDE, |
||||
| 113 | 25117625 |
US |
9 | 1 |
Febrile neutropenia, Disease progression, Disease recurrence, |
||||
TEMOZOLOMIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, ETOPOSIDE, |
||||
| 114 | 25117693 |
GB |
9 | 1 |
Disease progression, |
||||
NIFEDIPINE, NIFEDIPINE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 115 | 25118129 |
AU |
70 | 1 |
Disease progression, Drug intolerance, Drug ineffective, Therapeutic product effect incomplete, |
||||
GABAPENTIN, IPILIMUMAB, NIVOLUMAB, MORPHINE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, PEMETREXED, PEMETREXED DISODIUM, PREGABALIN, |
||||
| 116 | 25118207 |
CA |
56 | 1 |
Disease progression, Rash, Lip and/or oral cavity cancer, Off label use, |
||||
CAPECITABINE, |
||||
| 117 | 25118286 |
CN |
67 | 1 |
Disease progression, |
||||
BEVACIZUMAB, TEMOZOLOMIDE, SORAFENIB, |
||||
| 118 | 25118432 |
51 | ||
Adenocarcinoma of salivary gland, Disease progression, Lethargy, Off label use, Nail toxicity, Pain in extremity, |
||||
PEMIGATINIB, PEMIGATINIB, PEMIGATINIB, PEMIGATINIB, PEMIGATINIB, PEMIGATINIB, SUMATRIPTAN, SUMATRIPTAN SUCCINATE, MORPHINE SULFATE, FAMOTIDINE, PREGABALIN, |
||||
| 119 | 25118733 |
US |
82 | 1 |
Disease progression, |
||||
LENALIDOMIDE, |
||||
| 120 | 25118763 |
NO |
2 | |
Drug ineffective for unapproved indication, Disease progression, Off label use, |
||||
METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, LETROZOLE, LETROZOLE TABLETS, |
||||
| 121 | 25119164 |
US |
22 | 1 |
Drug ineffective, Disease progression, |
||||
DOXORUBICIN, IFOSFAMIDE, PAZOPANIB, PAZOPANIB HYDROCHLORIDE, |
||||
| 122 | 25119614 |
IT |
65 | |
Spontaneous haemorrhage, Disease progression, |
||||
ZANUBRUTINIB, OBINUTUZUMAB, OBINUTUZUMAB, BENDAMUSTINE HCL, |
||||
| 123 | 25119748 |
US |
2 | |
Disease progression, |
||||
RIBOCICLIB, |
||||
| 124 | 25119910 |
IT |
65 | 1 |
Disease progression, Drug ineffective, |
||||
TRIFLURIDINE AND TIPIRACIL, |
||||
| 125 | 25120619 |
RS |
71 | |
Disease progression, |
||||
DAPAGLIFLOZIN, |
||||
| 126 | 25110269 |
PK |
41 | 2 |
Disease progression, |
||||
RITUXIMAB, |
||||
| 127 | 25110394 |
FR |
56 | 2 |
Disease progression, |
||||
BEVACIZUMAB, OSIMERTINIB, AMIVANTAMAB, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 128 | 25110446 |
US |
5 | 2 |
Disease progression, Drug ineffective, |
||||
ATEZOLIZUMAB, CARBOPLATIN, ETOPOSIDE, LURBINECTEDIN, |
||||
| 129 | 25110820 |
GB |
2 | |
Motor neurone disease, Disease progression, Incorrect dose administered, |
||||
SOMATROPIN, |
||||
| 130 | 25110843 |
RU |
68 | 1 |
Acute kidney injury, Metastases to spine, Gastrointestinal disorder, Spondylolisthesis, Ill-defined disorder, Disease progression, Hydronephrosis, Nephropathy, |
||||
ATEZOLIZUMAB, ATEZOLIZUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, CISPLATIN, PACLITAXEL, |
||||
| 131 | 25110988 |
GB |
||
Disease progression, |
||||
CAPIVASERTIB, |
||||
| 132 | 25111027 |
CA |
29 | 1 |
Hyperferritinaemia, Pancytopenia, Lymphadenopathy, Splenomegaly, Hypofibrinogenaemia, Disease progression, Haemophagocytic lymphohistiocytosis, Pyrexia, Therapy non-responder, Product use in unapproved indication, |
||||
ANAKINRA, CYCLOSPORINE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ETOPOSIDE, ELTROMBOPAG, HUMAN IMMUNOGLOBULIN G, TOCILIZUMAB, PREDNISONE, |
||||
| 133 | 25111123 |
CA |
77 | 2 |
Disease progression, Confusional state, Blood calcium abnormal, Discomfort, Ophthalmoplegia, Treatment failure, |
||||
LENALIDOMIDE, CARFILZOMIB, DARATUMUMAB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, LENALIDOMIDE, |
||||
| 134 | 25111316 |
KW |
1 | |
Metastatic lymphoma, Disease progression, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, |
||||
| 135 | 25111446 |
SK |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 136 | 25111600 |
LB |
||
Disease progression, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, |
||||
| 137 | 25111808 |
GB |
57 | 2 |
Drug ineffective, Disease progression, |
||||
ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PYRIDOSTIGMINE BROMIDE ORAL, PYRIDOSTIGMINE BROMIDE ORAL, PYRIDOSTIGMINE BROMIDE ORAL, PYRIDOSTIGMINE BROMIDE ORAL, |
||||
| 138 | 25112370 |
US |
53 | 2 |
Drug ineffective, Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 139 | 25112774 |
55 | ||
Chronic graft versus host disease, Stomatitis, Disease progression, |
||||
RUXOLITINIB, RUXOLITINIB, RUXOLITINIB, RUXOLITINIB, CARVEDILOL, LISINOPRIL, MONTELUKAST SODIUM, OMEPRAZOLE MAGNESIUM, TOBRAMYCIN AND DEXAMETHASONE, ZOLPIDEM TARTRATE, PREDNISONE, |
||||
| 140 | 25113363 |
FR |
||
Disease progression, |
||||
TEBENTAFUSP, TEBENTAFUSP, |
||||
| 141 | 25113546 |
US |
56 | 1 |
Disease progression, Whipple^s disease, |
||||
LENALIDOMIDE, RITUXIMAB, RITUXIMAB, |
||||
| 142 | 25113599 |
PT |
37 | 2 |
Familial amyloidosis, Disease progression, Pupillary disorder, |
||||
TAFAMIDIS, |
||||
| 143 | 25113620 |
ES |
38 | 2 |
Enterococcal infection, Meningitis, Drug ineffective, Disease progression, |
||||
DOXORUBICIN, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, IFOSFAMIDE, ETOPOSIDE, CISPLATIN, CYTARABINE, |
||||
| 144 | 25113941 |
FR |
2 | |
Disease progression, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 145 | 25114945 |
US |
83 | 1 |
Metastases to bone, Disease progression, |
||||
CARBOPLATIN, CARBOPLATIN, CABAZITAXEL, CABAZITAXEL, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 146 | 25108228 |
US |
||
Disease progression, |
||||
LENALIDOMIDE, |
||||
| 147 | 25108267 |
ES |
72 | 2 |
Disease progression, Pulmonary embolism, Deep vein thrombosis, Ascites, Intestinal obstruction, Metastases to peritoneum, Metastases to muscle, |
||||
LETROZOLE, LETROZOLE TABLETS, RIPRETINIB, |
||||
| 148 | 25108282 |
CA |
68 | |
Disease progression, Pain, Therapy cessation, |
||||
DURVALUMAB, HYDROMORPHONE HYDROCHLORIDE, MORPHINE, |
||||
| 149 | 25108340 |
PK |
51 | 2 |
Disease progression, |
||||
BEVACIZUMAB, BEVACIZUMAB, |
||||
| 150 | 25108617 |
NL |
||
Pneumonitis, Peripheral sensory neuropathy, Disease progression, |
||||
CARBOPLATIN, PACLITAXEL, ATEZOLIZUMAB, BEVACIZUMAB, |
||||
| 151 | 25108707 |
GB |
||
Disease progression, Endocarditis, |
||||
RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, VINCRISTINE SULFATE, PREDNISONE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CISPLATIN, |
||||
| 152 | 25108725 |
US |
44 | 1 |
Drug ineffective, Disease progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 153 | 25108773 |
CN |
59 | 1 |
Disease progression, |
||||
OBINUTUZUMAB, |
||||
| 154 | 25108788 |
US |
78 | 1 |
Drug ineffective, Disease progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 155 | 25108789 |
US |
||
Drug ineffective, Disease progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, CARBOPLATIN, PEMBROLIZUMAB, SOTORASIB, SOTORASIB, SOTORASIB, |
||||
| 156 | 25108917 |
IN |
60 | 1 |
Disease progression, Cerebral disorder, |
||||
ATEZOLIZUMAB, |
||||
| 157 | 25102588 |
CY |
1 | |
Disease progression, Prostatic specific antigen abnormal, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 158 | 25102708 |
LB |
1 | |
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 159 | 25102750 |
PK |
47 | 2 |
Disease progression, |
||||
PERTUZUMAB, TRASTUZUMAB, |
||||
| 160 | 25102838 |
US |
73 | 1 |
Disease progression, |
||||
ABIRATERONE ACETATE, ABIRATERONE, |
||||
| 161 | 25102848 |
US |
52 | 1 |
Disease progression, |
||||
PREDNISONE, |
||||
| 162 | 25102852 |
US |
73 | 1 |
Disease progression, |
||||
TESTOSTERONE, TESTOSTERONE,, |
||||
| 163 | 25102857 |
TR |
3 | 1 |
Disease progression, |
||||
TEMOZOLOMIDE, |
||||
| 164 | 25102956 |
RU |
42 | 1 |
Disease progression, |
||||
OCTREOTIDE ACETATE, OCTREOTIDE, |
||||
| 165 | 25102958 |
CN |
59 | 2 |
Disease progression, |
||||
CARBOPLATIN, PACLITAXEL, BEVACIZUMAB, |
||||
| 166 | 25103087 |
PT |
43 | 1 |
Disease progression, Therapy partial responder, Haematotoxicity, |
||||
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM, FLUOROURACIL, FLUOROURACIL, BEVACIZUMAB, BEVACIZUMAB, CETUXIMAB, |
||||
| 167 | 25103204 |
JP |
53 | 2 |
Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, ETOPOSIDE, ETOPOSIDE, |
||||
| 168 | 25103227 |
DK |
76 | 1 |
Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, |
||||
| 169 | 25103281 |
PK |
63 | 2 |
Follicular lymphoma, Disease progression, |
||||
OBINUTUZUMAB, |
||||
| 170 | 25103318 |
PL |
45 | |
Anaphylactic shock, Disease progression, Splenomegaly, Leukopenia, Neutropenia, Thrombocytopenia, Acetabulum fracture, |
||||
RITUXIMAB, MOSUNETUZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, ETOPOSIDE, ETOPOSIDE, METHYLPREDNISOLONE, CYTARABINE, CISPLATIN, IFOSFAMIDE, CARBOPLATIN, BORTEZOMIB FOR INJECTION, BORTEZOMIB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, BENDAMUSTINE HCL, LENALIDOMIDE, |
||||
| 171 | 25103548 |
RU |
48 | 2 |
Anaemia, Thrombocytopenia, Hepatotoxicity, Disease progression, Metastases to bone, Pleural effusion, Spinal fracture, |
||||
TRASTUZUMAB, PERTUZUMAB, ADO-TRASTUZUMAB EMTANSINE, DOCETAXEL, DOCETAXEL ANHYDROUS, CARBOPLATIN, |
||||
| 172 | 25103576 |
JP |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 173 | 25103606 |
BR |
2 | |
Mental disorder, Ankylosing spondylitis, Disease progression, Asthenia, Pain, |
||||
SECUKINUMAB, |
||||
| 174 | 25103668 |
JP |
||
Disease progression, |
||||
MOMELOTINIB, |
||||
| 175 | 25103805 |
GB |
||
Endocarditis, Disease progression, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, VINCRISTINE SULFATE, PREDNISONE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 176 | 25103865 |
RU |
51 | 2 |
Disease progression, Lymphadenopathy, Hydrothorax, Osteosclerosis, Neoplasm, Pleural effusion, Atelectasis, Pulmonary mass, Metastases to central nervous system, Hepatic lesion, Lung neoplasm, |
||||
TRASTUZUMAB, PERTUZUMAB, ADO-TRASTUZUMAB EMTANSINE, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 177 | 25104124 |
DK |
80 | 2 |
Disease progression, Toxicity to various agents, |
||||
PEMETREXED, PEMETREXED DISODIUM, OSIMERTINIB, FOLIC ACID, |
||||
| 178 | 25104347 |
US |
75 | 2 |
Febrile neutropenia, Myelosuppression, Infection, Drug ineffective, Disease progression, Off label use, |
||||
ETOPOSIDE, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, CARBOPLATIN, THIOTEPA, |
||||
| 179 | 25104522 |
JP |
53 | 2 |
Disease progression, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, ETOPOSIDE, CISPLATIN, CISPLATIN, CISPLATIN, |
||||
| 180 | 25104541 |
TR |
42 | 2 |
Disease progression, Febrile neutropenia, Drug ineffective for unapproved indication, Mucosal inflammation, |
||||
ETOPOSIDE, BLEOMYCIN, BLEOMYCIN SULFATE, CISPLATIN, |
||||
| 181 | 25104569 |
JP |
1 | |
Disease progression, Drug ineffective for unapproved indication, |
||||
DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), DANTROLENE, TIZANIDINE, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, LEMBOREXANT, MIRTAZAPINE, FENTANYL, CLONAZEPAM, |
||||
| 182 | 25104610 |
AU |
54 | 1 |
Disease progression, Therapy partial responder, Alpha 1 foetoprotein increased, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, LENVATINIB, |
||||
| 183 | 25104765 |
CN |
54 | 1 |
Disease progression, Metabolic disorder, Drug intolerance, Gastrointestinal disorder, Pulmonary embolism, Vena cava thrombosis, Venous thrombosis limb, Hypertension, |
||||
RITUXIMAB, POLATUZUMAB VEDOTIN, |
||||
| 184 | 25104777 |
GB |
1 | |
Disease progression, |
||||
FRUQUINTINIB, |
||||
| 185 | 25104979 |
CN |
53 | 2 |
Disease progression, |
||||
CARBOPLATIN, PACLITAXEL, |
||||
| 186 | 25105128 |
GB |
73 | 1 |
Endocarditis, Disease progression, |
||||
CISPLATIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, VINCRISTINE SULFATE, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, RITUXIMAB, |
||||
| 187 | 25105132 |
AU |
||
Nervous system disorder, Disease progression, Drug intolerance, Drug ineffective, Cognitive disorder, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, PREGABALIN, PREGABALIN, CISPLATIN, FENTANYL, FENTANYL, GABAPENTIN, GABAPENTIN, IPILIMUMAB, KETAMINE HYDROCHLORIDE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, MORPHINE, MORPHINE, NIVOLUMAB, OXYCODONE, OXYCODONE, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 188 | 25105225 |
CN |
41 | 2 |
Myelosuppression, Off label use, Disease progression, Abdominal pain, Decreased appetite, |
||||
GEMCITABINE HYDROCHLORIDE, |
||||
| 189 | 25105345 |
US |
70 | 1 |
Disease progression, Metastasis, |
||||
BEVACIZUMAB, FLUOROURACIL, FLUOROURACIL, FLUOROURACIL, FLUOROURACIL, FLUOROURACIL, OXALIPLATIN, OXALIPLATIN, PANITUMUMAB, DOXYCYCLINE, DOXYCYCLINE HYCLATE, |
||||
| 190 | 25106476 |
SK |
32 | 2 |
Disease progression, |
||||
OFATUMUMAB, |
||||
| 191 | 25106549 |
CZ |
60 | 1 |
Disease progression, |
||||
RITUXIMAB, OBINUTUZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, ZANUBRUTINIB, IDELALISIB, BENDAMUSTINE HCL, |
||||
| 192 | 25106900 |
GB |
||
Disease progression, |
||||
VENETOCLAX, |
||||
| 193 | 25106926 |
US |
||
Disease progression, |
||||
OSIMERTINIB, |
||||
| 194 | 25107034 |
AT |
48 | 2 |
Disease progression, |
||||
DATOPOTAMAB DERUXTECAN, DATOPOTAMAB DERUXTECAN, |
||||
| 195 | 25107281 |
BE |
1 | |
Heart rate decreased, Disease progression, |
||||
TAFAMIDIS, |
||||
| 196 | 25107321 |
US |
2 | |
Disease progression, |
||||
TRIFLURIDINE AND TIPIRACIL, |
||||
| 197 | 25097356 |
US |
||
Injection site abscess sterile, Disease progression, Injection site oedema, Condition aggravated, Injection site pain, |
||||
LEUPROLIDE ACETATE, |
||||
| 198 | 25097410 |
LT |
50 | 2 |
Condition aggravated, Disease progression, Drug ineffective, Illness, Ileus, Vomiting, Abdominal pain, Oral fungal infection, |
||||
CARBOPLATIN, TOPOTECAN, |
||||
| 199 | 25097683 |
RU |
72 | 1 |
Pneumothorax spontaneous, Rheumatoid arthritis-associated interstitial lung disease, Disease progression, |
||||
NINTEDANIB, |
||||
| 200 | 25097685 |
IT |
49 | 2 |
Osteonecrosis of jaw, Disease progression, Therapeutic product effect incomplete, Metastasis, |
||||
LETROZOLE, LETROZOLE TABLETS, ZOLEDRONIC ACID, DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28